SCYNEXIS Inc is a drug development company that focuses on the development and commercialization of novel anti-infectives to address unmet therapeutic needs... Show more
SCYX's Aroon Indicator triggered a bullish signal on May 06, 2025. Tickeron's A.I.dvisor detected that the AroonUp green line is above 70 while the AroonDown red line is below 30. When the up indicator moves above 70 and the down indicator remains below 30, it is a sign that the stock could be setting up for a bullish move. Traders may want to buy the stock or look to buy calls options. A.I.dvisor looked at 104 similar instances where the Aroon Indicator showed a similar pattern. In of the 104 cases, the stock moved higher in the days that followed. This puts the odds of a move higher at .
The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where SCYX's RSI Indicator exited the oversold zone, of 42 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are .
The Stochastic Oscillator is in the oversold zone. Keep an eye out for a move up in the foreseeable future.
The Moving Average Convergence Divergence (MACD) for SCYX just turned positive on April 14, 2025. Looking at past instances where SCYX's MACD turned positive, the stock continued to rise in of 42 cases over the following month. The odds of a continued upward trend are .
SCYX moved above its 50-day moving average on May 07, 2025 date and that indicates a change from a downward trend to an upward trend.
The 10-day moving average for SCYX crossed bullishly above the 50-day moving average on May 01, 2025. This indicates that the trend has shifted higher and could be considered a buy signal. In of 13 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are .
Following a +1 3-day Advance, the price is estimated to grow further. Considering data from situations where SCYX advanced for three days, in of 230 cases, the price rose further within the following month. The odds of a continued upward trend are .
The Momentum Indicator moved below the 0 level on May 06, 2025. You may want to consider selling the stock, shorting the stock, or exploring put options on SCYX as a result. In of 79 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .
Following a 3-day decline, the stock is projected to fall further. Considering past instances where SCYX declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
SCYX broke above its upper Bollinger Band on April 24, 2025. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.766) is normal, around the industry mean (61.504). P/E Ratio (1.065) is within average values for comparable stocks, (90.857). SCYX's Projected Growth (PEG Ratio) (0.000) is slightly lower than the industry average of (2.987). Dividend Yield (0.000) settles around the average of (0.122) among similar stocks. P/S Ratio (0.511) is also within normal values, averaging (19.413).
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating fairly steady price growth. SCYX’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. SCYX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 90, placing this stock worse than average.
a company which engages in discovery, development and commercialization of novel anti infectives
Industry PharmaceuticalsOther
A.I.dvisor indicates that over the last year, SCYX has been loosely correlated with AKAN. These tickers have moved in lockstep 35% of the time. This A.I.-generated data suggests there is some statistical probability that if SCYX jumps, then AKAN could also see price increases.
Ticker / NAME | Correlation To SCYX | 1D Price Change % | ||
---|---|---|---|---|
SCYX | 100% | -0.41% | ||
AKAN - SCYX | 35% Loosely correlated | +4.29% | ||
TXMD - SCYX | 30% Poorly correlated | +1.25% | ||
OGI - SCYX | 30% Poorly correlated | -0.89% | ||
AQST - SCYX | 28% Poorly correlated | +1.10% | ||
ACET - SCYX | 27% Poorly correlated | -2.45% | ||
More |